A citation-based method for searching scientific literature

Jonathan J Lo, Meghan M Heberton, Omar Pacha, Auris O Huen, Anisha B Patel. Support Care Cancer 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Immune checkpoint inhibitor-related dermatologic adverse events.
Amaris N Geisler, Gregory S Phillips, Dulce M Barrios, Jennifer Wu, Donald Y M Leung, Andrea P Moy, Jeffrey A Kern, Mario E Lacouture. J Am Acad Dermatol 2020
80
100

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Suzanne L Topalian, Mario Sznol, David F McDermott, Harriet M Kluger, Richard D Carvajal, William H Sharfman, Julie R Brahmer, Donald P Lawrence, Michael B Atkins, John D Powderly,[...]. J Clin Oncol 2014
100

Skin Reactions to Immune Checkpoint Inhibitors.
Anisha B Patel, Omar Pacha. Adv Exp Med Biol 2020
3
100

Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
Veronica J Shi, Nemanja Rodic, Scott Gettinger, Jonathan S Leventhal, Julia P Neckman, Michael Girardi, Marcus Bosenberg, Jennifer N Choi. JAMA Dermatol 2016
122
100

Oral mucositis.
Vibha Singh, Akhilesh Kumar Singh. Natl J Maxillofac Surg 2020
7
100

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.
Morganna Freeman-Keller, Youngchul Kim, Heather Cronin, Allison Richards, Geoffrey Gibney, Jeffrey S Weber. Clin Cancer Res 2016
510
100

Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
Michael T Tetzlaff, Priyadharsini Nagarajan, Susan Chon, Auris Huen, Adi Diab, Pacha Omar, Phyu P Aung, Carlos A Torres-Cabala, Steven R Mays, Victor G Prieto,[...]. Am J Dermatopathol 2017
60
100

Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
Charles Kyung Min Lee, Shufeng Li, Duy Cong Tran, Gefei Alex Zhu, Jinah Kim, Bernice Y Kwong, Anne Lynn S Chang. J Am Acad Dermatol 2018
63
100

The impact of pruritus on quality of life: the skin equivalent of pain.
Seema P Kini, Laura K DeLong, Emir Veledar, Anne Marie McKenzie-Brown, Michael Schaufele, Suephy C Chen. Arch Dermatol 2011
191
100

Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.
Vincent Sibaud, Nicolas Meyer, Laurence Lamant, Emmanuelle Vigarios, Julien Mazieres, Jean Pierre Delord. Curr Opin Oncol 2016
132
100

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.
Camille Hua, Lise Boussemart, Christine Mateus, Emilie Routier, Céline Boutros, Hugo Cazenave, Roxane Viollet, Marina Thomas, Séverine Roy, Naima Benannoune,[...]. JAMA Dermatol 2016
394
100

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Julie R Brahmer, Christina Lacchetti, Bryan J Schneider, Michael B Atkins, Kelly J Brassil, Jeffrey M Caterino, Ian Chau, Marc S Ernstoff, Jennifer M Gardner, Pamela Ginex,[...]. J Clin Oncol 2018
100

Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy.
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi. Future Oncol 2021
51
100

Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.
Jonathan L Curry, Michael T Tetzlaff, Priyadharsini Nagarajan, Carol Drucker, Adi Diab, Sharon R Hymes, Madeleine Duvic, Wen-Jen Hwu, Jennifer A Wargo, Carlos A Torres-Cabala,[...]. J Cutan Pathol 2017
123
100

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Christopher D Lao, C Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer,[...]. N Engl J Med 2019
100

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Julia A Brown, David M Dorfman, Feng-Rong Ma, Elizabeth L Sullivan, Oliver Munoz, Clive R Wood, Edward A Greenfield, Gordon J Freeman. J Immunol 2003
707
100

Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.
Hansje-Eva Teulings, Jacqueline Limpens, Sophia N Jansen, Aeilko H Zwinderman, Johannes B Reitsma, Phyllis I Spuls, Rosalie M Luiten. J Clin Oncol 2015
362
100

Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis.
Francesco Massari, Veronica Mollica, Alessandro Rizzo, Laura Cosmai, Mimma Rizzo, Camillo Porta. Expert Opin Drug Saf 2020
43
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.